Share Issue 2024

In order to finance continued development of AlzeCure’s drug candidates and to strengthen the Company’s financial position, the Company is carrying out a rights issue. As the Company is in discussions with several actors about possible license and/or cooperation deals, the Board of Directors makes the assessment that it is valuable to strengthen the cash position in order to obtain better negotiation position, and in the meantime, enable continued development of the Company’s research portfolio to increase the value and attractiveness of the assets. This includes Alzstatin where the focus now is to drive continued development of the platform’s candidates in preclinical development phase to enable the identification of a final potential clinical candidate. Furthermore, the Company will work with the continued development of the TrkA-NAM project, where the focus is to drive the continued development of ACD137 in preclinical development phase, towards the clinic. In consultation with leading researchers and experts in the field, the Company will also continue to plan the upcoming phase II study for NeuroRestore ACD856, which takes into account the obtained new preclinical results. Furthermore, the Company will work on new clinical plans for upcoming phase II studies for ACD440.

Summary

Type of Issue: Share Issue with preferential rights for existing shareholders 

Total Amount: Approximately SEK 52.8 million 

Subscription Terms: Two (2) existing shares in AlzeCure entitle the shareholder to subscribe for one (1) new share 

Subscription Price: SEK 1.70 per share 

Guaranteed: To approximately 63 percent through subscription commitments and guarantee commitments from existing shareholders and members of the Company’s management and Board of Directors 

Over-allotment Option: Up to approximately SEK 15.0 million 

Maximum Capital Contribution including Full Exercise of Over-allotment Option: Approximately SEK 67.8 MSEK 

Preliminary schedule for the Rights Issue